2018
39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY
Breier A, Dickerson F, Buchanan R, Marder S, Neuchterlein K, D’Souza D, Francis M, Radnovich A, Yolken R, Preskorn S, Macaluso M, Yang Z, Mehdyoun N, Kakar R, Dunn W, Hoffmeyer D, Maguire G. 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY. Schizophrenia Bulletin 2018, 44: s63-s63. PMCID: PMC5888721, DOI: 10.1093/schbul/sby014.162.Peer-Reviewed Original ResearchEarly phase schizophreniaHSV-1 seropositiveHSV-1Cognitive impairmentNegative subjectsHerpes virusPrevious small clinical trialsDuration of psychosisEfficacy of valacyclovirDouble-blind trialSmall clinical trialsHerpes virus infectionHerpes simplex virus type 1Treatment of schizophreniaSimplex virus type 1Life-long infectionVirus type 1Treatment outcome analysisMemory scoresFull therapeutic potentialPlacebo groupAdjunctive placeboInflammatory markersPrimary outcomeHuman CNS
2014
HepG2 cells mount an effective antiviral interferon‐lambda based innate immune response to hepatitis C virus infection
Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon‐lambda based innate immune response to hepatitis C virus infection. Hepatology 2014, 60: 1170-1179. PMID: 24833036, PMCID: PMC4176518, DOI: 10.1002/hep.27227.Peer-Reviewed Original ResearchConceptsInnate immune responseHCV infectionHuh-7.5 cellsInnate immune systemImmune responseImmune systemAntiviral responseEntire HCV life cycleHepatitis C virus exposurePersistent life-long infectionHepatitis C virus infectionMelanoma differentiation-associated protein 5C virus infectionRobust antiviral responseImportance of IFNHuh-7Retinoic acid-inducible gene IHCV life cycleAcid-inducible gene ILife-long infectionInnate immune antagonistsHepG2 cellsLike receptor pathwayLiver-specific microRNAHCV recognition
1994
Prevention of HIV/AIDS with vaccines
Vermund S, Schultz A, Hoff R. Prevention of HIV/AIDS with vaccines. Current Opinion In Infectious Diseases 1994, 7: 82-94. DOI: 10.1097/00001432-199402000-00014.Peer-Reviewed Original ResearchHIV vaccineVaccine preparedness studyPhase II trialPhase III trialsHigh-risk populationHuman phase IViral envelope antigensHIV vaccine efficacyHigh behavioral riskLife-long infectionHIV/AIDSRecombinant subunit vaccinesEnvelope vaccinesHIV vaccinationII trialIII trialsClinical updateVaccine efficacyPreventive counselingEffective vaccineEfficacy trialsEnvelope antigenFirst vaccineTrial participantsLive vector
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply